TRACON Secures FDA Nod For Early-Stage Study In Soft-Tissue Cancer

• The FDA has signed off TRACON Pharmaceuticals Inc's (NASDAQ: TCON) initiation of a Phase 1/2 trial of YH001 in combination with envafolimab and doxorubicin in sarcoma patients, including those who have not received prior therapy.

• The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma.

• Related: TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications.

• Additionally, the safety and efficacy of YH001, envafolimab, and doxorubicin will be assessed in the more prevalent sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.

• YH001, an IgG1 antibody against CTLA-4, has shown enhanced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.

• Price Action: TCON shares are up 0.50% at $2.02 on the last check Monday.

See more from Benzinga

• Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug

• Switzerland Approves First Next-Generation Bivalent COVID-19 Booster Vaccine

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.